玻璃体腔注射雷珠单抗治疗玻璃体切除和未切除眼中糖尿病性黄斑水肿的疗效比较
Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes.
作者信息
Koyanagi Yoshito, Yoshida Shigeo, Kobayashi Yoshiyuki, Kubo Yuki, Yamaguchi Muneo, Nakama Takahito, Nakao Shintaro, Ikeda Yasuhiro, Ohshima Yuji, Ishibashi Tatsuro, Sonoda Koh-Hei
机构信息
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
出版信息
Ophthalmologica. 2016;236(2):67-73. doi: 10.1159/000446992. Epub 2016 Jul 1.
PURPOSE
To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy.
PROCEDURES
We prospectively assessed the best-corrected visual acuity (BCVA) and central macular thickness (CMT) after IVR for 6 months.
RESULTS
There were no significant differences in the baseline BCVA and CMT between both groups. In the nonvitrectomized group (n = 15), the mean changes of BCVA and CMT from baseline to month 6 were significant (p < 0.01). In the vitrectomized group (n = 10), the improvement appeared to be slower, and the mean BCVA improvement was not significant (p = 0.5), although the mean CMT decrease was significant (p < 0.05). There were no significant differences in the mean changes of BCVA and CMT between both groups at 6 months.
CONCLUSIONS
The difference in the effectiveness of IVR between both groups was not significant. IVR can be a treatment option even for vitrectomized DME eyes.
目的
比较玻璃体内注射雷珠单抗（IVR）治疗糖尿病性黄斑水肿（DME）时，既往接受过玻璃体切割术的眼与未接受过玻璃体切割术的眼的疗效。
方法
我们前瞻性评估了IVR治疗6个月后的最佳矫正视力（BCVA）和中心黄斑厚度（CMT）。
结果
两组之间的基线BCVA和CMT无显著差异。在未接受玻璃体切割术的组（n = 15）中，从基线到第6个月，BCVA和CMT的平均变化具有显著性（p < 0.01）。在接受玻璃体切割术的组（n = 10）中，改善似乎较慢，尽管CMT平均下降具有显著性（p < 0.05），但BCVA的平均改善不显著（p = 0.5）。两组在6个月时BCVA和CMT的平均变化无显著差异。
结论
两组之间IVR疗效的差异不显著。IVR即使对于接受过玻璃体切割术的DME眼也可以作为一种治疗选择。
Zotero 插件